Rate My Professor Eli Kotler

Kotler's research specializations include neuropsychiatric therapeutics, addiction, trauma, and neurodegenerative diseases. He has acted as Principal Investigator for clinical trials such as a Phase 2a open-label study of MDMA-assisted psychotherapy for severe PTSD sponsored by Emyria, and Alfred Health trials including Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer’s Disease on Donepezil (MINDSET, 2015–2016), Lu AE58054 in Patients With Mild to Moderate Alzheimer’s Disease (STARBRIGHT, 2013–2015), and studies on EVP-6124 and S 38093 for Alzheimer’s. He co-authored the 2016 review article 'Missed diagnosis: the emerging crisis of borderline personality disorder in older people' published through Monash University research output. As an educator, he oversees the clinical addiction rotation for Monash University medical students at Alfred Hospital, applying neuropsychoanalytic principles, and received the 2017 Alfred Health Award for Best Medical Student Educator in Psychiatry. He contributes as a Teaching Faculty member for Mind Medicine Australia’s Certificate in Psychedelic-Assisted Therapies, serves on the board of Mind Medicine Australia since 2020, and is a regular speaker at national and international conferences on mental health, trauma, addiction, and psychedelics. He also sits on the advisory committee for the annual national addiction conference.